An innovation passport, the first step in the U.K.’s Innovative Licensing and Access Pathway (ILAP) — intended to accelerate the development and approval of new therapies that address an unmet medical need — has been awarded to AD04, ADvantage Therapeutics’ investigational immunotherapy for mild Alzheimer’s disease. The designation, granted…
DISCERN, a biomarker test reported to accurately diagnose Alzheimer’s disease at its earliest stages, routinely would be used by 90% of physicians who responded to a recent survey. With a positive test using a small skin sample, physicians were some six times more likely to diagnose Alzheimer’s and nearly three times…
Lecanemab (BAN2401), an amyloid-targeted antibody therapy for early Alzheimer’s disease, has been granted priority review in Japan, according to Eisai and Biogen, its developers. Priority review, as designated by the Japanese Ministry of Health, Labour and Welfare (MHLW), shortens the review period of applications seeking approval…
About 1.5 years of treatment with lecanemab (BAN2401) — now under regulatory review in the U.S. — was found to significantly slow the progression of dementia symptoms in people with early-onset Alzheimer’s disease. That’s according to just-released full data from the Phase 3 Clarity AD clinical trial, which showed…
The experimental therapy gantenerumab did not significantly slow clinical decline in people with early Alzheimer’s disease, failing to meet a primary trial goal, data from the Phase 3 GRADUATE 1 and 2 studies showed. Gantenerumab’s ability to remove beta-amyloid — the protein that forms plaques in patients’ brains…
Three years of a daily multivitamin-mineral supplement improved memory, and cognitive and executive function in older adults, according to data from the COSMOS-Mind study. Three years of administering cocoa extract every day had no effect on cognitive function, however. “This is the first positive, large-scale, long-term study to show that…
The toxic clumping of amyloid-beta, one of two key proteins implicated in Alzheimer’s disease, causes living human cells to generate heat, which may cause more clumps to form, a study suggests. “Overheating a cell is like frying an egg — as it heats up, the proteins start to clump…
Higher levels of small high-density lipoprotein (HDL), known as “good cholesterol,” in the fluid surrounding the brain and spinal cord associated with a better performance on cognitive tests in older adults, a study reported. Confirmation of a link between good cholesterol levels and cognitive outcomes in larger groups could lead…
Improved access to high-quality healthcare and research for Latinos living with Alzheimer’s disease and related dementia are needed, according to a summary report from the second Latinos & Alzheimer’s Symposium. Understanding underlying disease-related processes unique to Latino populations, and identifying social and environmental risk factors for this group also…
Up to 18% of U.S. participants in ENVISION — a Phase 4 post-marketing study of Aduhelm (aducanumab) in early Alzheimer’s disease — will now be enrolled from African American and Latinx populations, the therapy’s developers said in a press release. The aim is to increase diversity in the trial,…
Get regular updates to your inbox.